Emmessar Biotech FY26 Net Profit Rises 38% YoY

Board approved audited standalone financial results for FY26, reporting a net profit of ₹43.59 lakhs, a 38% increase year-on-year.
Statutory auditors V. Nagarajan & Co. issued an unmodified audit opinion on the results, confirming compliance with SEBI LODR regulations.
The company operates in two segments: Healthcare and Rent on leasehold land, with total income for the year at ₹240.66 lakhs.
Paid-up equity share capital remained unchanged at ₹499.61 lakhs, with earnings per share (basic and diluted) at ₹0.81 for FY26.